The life cycle of a T cell after vaccination – where does immune ageing strike?

Clinical and Experimental Immunology

Volumn 187, Issue 1, 2017, Pages 71-81

  Kim, C ^a   Fang, F ^a   Weyand, C M ^a   Goronzy, J J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

aging; immunosenescence; T cell memory; T cell receptor repertoire; T cell response

Indexed keywords

AGING; APOPTOSIS; CELL CYCLE; CELL EXPANSION; CELL LINE; CELL SURVIVAL; DISEASE MODEL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOSENESCENCE; LYMPHOCYTE ACTIVATION; PROCEDURES;

IMMUNOLOGICAL ADJUVANT;

ADJUVANTS, IMMUNOLOGIC; AGING; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSENESCENCE; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VACCINATION;

EID: 84981507330     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12829     Document Type: Review

References (96)

1. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009; 21:201–9.
2. Sasaki S, Sullivan M, Narvaez CF et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011; 121:3109–19.
3. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272:1661–5.
4. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123:518–27.
5. Jefferson TD, Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2:CD004876.
6. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013; 31:6030–3.
7. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLOS Med 2013; 10:e1001420
8. Schmader KE, Levin MJ, Gnann JW, Jr et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922–8.
9. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160–6.
10. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271–84.
11. Black S, De Gregorio E, Rappuoli R. Developing vaccines for an aging population. Sci Transl Med 2015; 7:281ps8.
12. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172–80.
13. Dolin R. The quadrivalent approach to influenza vaccination. J Infect Dis 2013; 208:539–40.
14. DiazGranados CA, Dunning AJ, Kimmel M et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635–45.
15. Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol 2015; 386:151–80.
16. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19:1597–608.
17. Van Buynder PG, Konrad S, Van Buynder JL et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31:6122–8.
18. McElhaney JE, Beran J, Devaster JM et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485–96.
19. Lal H, Cunningham AL, Godeaux O et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087–96.
20. Pulendran B. Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci USA 2014; 111:12300–6.
21. Duraisingham SS, Rouphael N, Cavanagh MM, Nakaya HI, Goronzy JJ, Pulendran B. Systems biology of vaccination in the elderly. Curr Top Microbiol Immunol 2013; 363:117–42.
22. Nakaya HI, Hagan T, Duraisingham SS et al. Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity 2015; 43:1186–98.
23. Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 2015; 16:142–52.
24. Levin MJ, Smith JG, Kaufhold RM et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336–44.
25. Haberthur K, Engelmann F, Park B et al. CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLOS Pathog 2011; 7:e1002367
26. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347:26–34.
27. Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305–12.
28. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274–80.
29. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333–9.
30. McElhaney JE, Ewen C, Zhou X et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418–25.
31. Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis 2015; 60:1170–5.
32. McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol 2010; 8:37.
33. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007; 25:171–92.
34. van Heijst JW, Gerlach C, Swart E et al. Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science 2009; 325:1265–9.
35. Moon JJ, Chu HH, Pepper M et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007; 27:203–13.
36. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008; 28:859–69.
37. Kwok WW, Tan V, Gillette L et al. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J Immunol 2012; 188:2537–44.
38. Briceno O, Lissina A, Wanke K et al. Reduced naive CD8(+) T-cell priming efficacy in elderly adults. Aging Cell 2016; 15:14–21.
39. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14:428–36.
40. Qi Q, Liu Y, Cheng Y et al. Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci USA 2014; 111:13139–44.
41. Quinn KM, Zaloumis SG, Cukalac T et al. Heightened self-reactivity associated with selective survival, but not expansion, of naive virus-specific CD8+ T cells in aged mice. Proc Natl Acad Sci USA 2016; 113:1333–8.
42. Deshpande NR, Parrish HL, Kuhns MS. Self-recognition drives the preferential accumulation of promiscuous CD4(+) T-cells in aged mice. Elife 2015; 4:e05949.
43. Kim C, Williams MA. Nature and nurture: T-cell receptor-dependent and T-cell receptor-independent differentiation cues in the selection of the memory T-cell pool. Immunology 2010; 131:310–7.
44. La Gruta NL, Rothwell WT, Cukalac T et al. Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J Clin Invest 2010; 120:1885–94.
45. Malherbe L, Hausl C, Teyton L, McHeyzer-Williams MG. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity 2004; 21:669–79.
46. Kim C, Wilson T, Fischer KF, Williams MA. Sustained interactions between T cell receptors and antigens promote the differentiation of CD4(+) memory T cells. Immunity 2013; 39:508–20.
47. Williams MA, Ravkov EV, Bevan MJ. Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 2008; 28:533–45.
48. Teixeiro E, Daniels MA, Hamilton SE et al. Different T cell receptor signals determine CD8+ memory versus effector development. Science 2009; 323:502–5.
49. Cukalac T, Chadderton J, Handel A et al. Reproducible selection of high avidity CD8+ T-cell clones following secondary acute virus infection. Proc Natl Acad Sci USA 2014; 111:1485–90.
50. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 1999; 10:485–92.
51. Joshi NS, Cui W, Chandele A et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27:281–95.
52. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 2008; 205:625–40.
53. Marshall HD, Chandele A, Jung YW et al. Differential expression of Ly6C and T-bet distinguish effector and memory Th1 CD4(+) cell properties during viral infection. Immunity 2011; 35:633–46.
54. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010; 32:79–90.
55. Prabhu N, Ho AW, Wong KH et al. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population. J Virol 2013; 87:12510–22.
56. Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 2010; 32:91–103.
57. Cui W, Liu Y, Weinstein JS, Craft J, Kaech SM. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 2011; 35:792–805.
58. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108–12.
59. Zhang L, Tschumi BO, Lopez-Mejia IC et al. Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a Foxo1-dependent manner. Cell Rep 2016; 14:1206–17.
60. Palmer DB. The effect of age on thymic function. Front Immunol 2013; 4:316
61. Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev 2005; 205:72–93.
62. Qi Q, Zhang DW, Weyand CM, Goronzy JJ. Mechanisms shaping the naive T cell repertoire in the elderly - thymic involution or peripheral homeostatic proliferation? Exp Gerontol 2014; 54:71–4.
63. den Braber I, Mugwagwa T, Vrisekoop N et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 2012; 36:288–97.
64. Nikolich-Zugich J, Li G, Uhrlaub JL, Renkema KR, Smithey MJ. Age-related changes in CD8 T cell homeostasis and immunity to infection. Semin Immunol 2012; 24:356–64.
65. Czesnikiewicz-Guzik M, Lee WW, Cui D et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008; 127:107–18.
66. Schulz AR, Malzer JN, Domingo C et al. Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans. J Immunol 2015; 195:4699–711.
67. Britanova OV, Putintseva EV, Shugay M et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol 2014; 192:2689–98.
68. Goronzy JJ, Qi Q, Olshen RA, Weyand CM. High-throughput sequencing insights into T-cell receptor repertoire diversity in aging. Genome Med 2015; 7:117.
69. Johnson PL, Yates AJ, Goronzy JJ, Antia R. Peripheral selection rather than thymic involution explains sudden contraction in naive CD4 T-cell diversity with age. Proc Natl Acad Sci USA 2012; 109:21432–7.
70. Qi Q, Cavanagh MM, Le Saux S et al. Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med 2016; 8:332ra46
71. Li QJ, Chau J, Ebert PJ et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129:147–61.
72. Li G, Yu M, Lee WW et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med 2012; 18:1518–24.
73. Cavanagh MM, Qi Q, Weyand CM, Goronzy JJ. Finding balance: T cell regulatory receptor expression during aging. Aging Dis 2011; 2:398–413.
74. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492–9.
75. Lamar DL, Weyand CM, Goronzy JJ. Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages. Blood 2010; 115:3278–86.
76. Dolfi DV, Mansfield KD, Polley AM et al. Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. J Leukoc Biol 2013; 93:825–36.
77. Akbar AN, Henson SM. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 2011; 11:289–95.
78. Lee KA, Shin KS, Kim GY et al. Characterization of age-associated exhausted CD8(+) T cells defined by increased expression of Tim-3 and PD-1. Aging Cell 2016; 15:291–300.
79. Brenchley JM, Karandikar NJ, Betts MR et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101:2711–20.
80. Henel G, Singh K, Cui D et al. Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. Blood 2006; 107:4449–57.
81. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152:522–31.
82. Lin Y, Damjanovic A, Metter EJ et al. Age-associated telomere attrition of lymphocytes in vivo is co-ordinated with changes in telomerase activity, composition of lymphocyte subsets and health conditions. Clin Sci (Lond) 2015; 128:367–77.
83. Chen W, Kimura M, Kim S et al. Longitudinal versus cross-sectional evaluations of leukocyte telomere length dynamics: age-dependent telomere shortening is the rule. J Gerontol A Biol Sci Med Sci 2011; 66:312–9.
84. Liu Y, Sanoff HK, Cho H et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009; 8:439–48.
85. Henson SM, Macaulay R, Riddell NE, Nunn CJ, Akbar AN. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. Eur J Immunol 2015; 45:1441–51.
86. Henson SM, Lanna A, Riddell NE et al. p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8(+) T cells. J Clin Invest 2014; 124:4004–16.
87. Di Mitri D, Azevedo RI, Henson SM et al. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J Immunol 2011; 187:2093–100.
88. Wrammert J, Onlamoon N, Akondy RS et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 2012; 86:2911–8.
89. Wrammert J, Smith K, Miller J et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667–71.
90. Herati RS, Reuter MA, Dolfi DV et al. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol 2014; 193:3528–37.
91. Yu M, Li G, Lee WW et al. Signal inhibition by the dual-specific phosphatase 4 impairs T cell-dependent B-cell responses with age. Proc Natl Acad Sci USA 2012; 109:E879–88.
92. Bignon A, Regent A, Klipfel L et al. DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia. Blood 2015; 125:2507–18.
93. Tresini M, Lorenzini A, Torres C, Cristofalo VJ. Modulation of replicative senescence of diploid human cells by nuclear ERK signaling. J Biol Chem 2007; 282:4136–51.
94. Shiow LR, Rosen DB, Brdickova N et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440:540–4.
95. Li G, Ju J, Weyand CM, Goronzy JJ. Age-associated failure to adjust type I IFN receptor signaling thresholds after T cell activation. J Immunol 2015; 195:865–74.
96. Fang F, Yu M, Cavanagh MM et al. Expression of CD39 on activated T cells impairs their survival in older individuals. Cell Rep 2016; 14:1218–31.